Martin Babler is CEO & President at Principia Biopharma Inc. (PRNB). They have made 6 open-market trades across 2 companies since 2019, most recently 2026-06-23.
CIK 0001435618
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $101K since 2025, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALMS | BUY | 2025-04-01 | 2025-04-03 | $6.44 | $101K | -39.7% | -48.1% | -61.3% |
| PRNB | SELL | 2020-06-23 | 2020-06-25 | $61.89 | $1.8M | -4.0% | +50.9% | +70.2% |
| PRNB | SELL | 2020-03-03 | 2020-03-05 | $63.46 | $1.9M | -28.9% | -9.9% | -2.6% |
| PRNB | SELL | 2019-12-18 | 2019-12-19 | $53.66 | $241K | -8.6% | -0.9% | -28.5% |
| PRNB | SELL | 2019-12-17 | 2019-12-19 | $53.21 | $2.8M | -8.6% | -0.9% | -28.5% |
| PRNB | SELL | 2019-12-17 | 2019-12-19 | $52.96 | $1.3M | -8.6% | -0.9% | -28.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.